Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study.

Shimoda H, Nakamura Y, Inoue M, Yoshinaga A, Kawamura N, Yonese I, Izumi K, Yamamoto T, Uehara S, Suzuki K, Toide M, Takazawa R, Araki S, Fukushima H, Fukuda S, Yuma W, Tanaka H, Yoshida S, Fujii Y

Open source

DOI: 10.1111/iju.70486
Published: 2026 May
Container: International journal of urology : official journal of the Japanese Urological Association
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/iju.70486,
  title = {Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study.},
  author = {Shimoda H and Nakamura Y and Inoue M and Yoshinaga A and Kawamura N and Yonese I and Izumi K and Yamamoto T and Uehara S and Suzuki K and Toide M and Takazawa R and Araki S and Fukushima H and Fukuda S and Yuma W and Tanaka H and Yoshida S and Fujii Y},
  year = {2026},
  journal = {International journal of urology : official journal of the Japanese Urological Association},
  doi = {10.1111/iju.70486},
  url = {https://doi.org/10.1111/iju.70486}
}

RIS

TY  - JOUR
TI  - Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study.
AU  - Shimoda H
AU  - Nakamura Y
AU  - Inoue M
AU  - Yoshinaga A
AU  - Kawamura N
AU  - Yonese I
AU  - Izumi K
AU  - Yamamoto T
AU  - Uehara S
AU  - Suzuki K
AU  - Toide M
AU  - Takazawa R
AU  - Araki S
AU  - Fukushima H
AU  - Fukuda S
AU  - Yuma W
AU  - Tanaka H
AU  - Yoshida S
AU  - Fujii Y
PY  - 2026
JO  - International journal of urology : official journal of the Japanese Urological Association
DO  - 10.1111/iju.70486
UR  - https://doi.org/10.1111/iju.70486
ER  -

APA

H, S., Y, N., M, I., A, Y., N, K., I, Y., K, I., T, Y., S, U., K, S., M, T., R, T., S, A., H, F., S, F., W, Y., H, T., S, Y., & Y, F. (2026). Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study.. International journal of urology : official journal of the Japanese Urological Association. https://doi.org/10.1111/iju.70486

Source records

pubmed · retrieved 2026-09-26T16:46:50.566Z